Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRA548)

Drug Name
N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide Drug Info
Synonyms
N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide; N-cyclohexyl-2-oxochromene-3-carboxamide; 2-Oxo-2H-chromene-3-carboxylic acid cyclohexylamide; 4021-23-2; BAS 00837943; ChemDiv2_003298; 3-carboxamido coumarin, 1; AC1Q5N8P; AC1LF7K7; Oprea1_254332; Oprea1_273725; CHEMBL472080; BDBM29152; CTK1C9968; DTXSID70352366; MolPort-001-028-458; ZINC130287; HMS1378F20; CCG-15837; STK408165; AKOS000533315; MCULE-8945496486; N-cyclohexyl(2-oxochromen-3-yl)carboxamide; EU-0035943; ST50185340; SR-01000410421; SR-01000410421-1
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
724217
CAS Number
CAS 4021-23-2
TTD Drug ID
DMRA548

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Monoamine oxidase type B (MAO-B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selegiline Hydrochloride DM3VR1L Parkinson disease 8A00.0 Approved [2]
Phenelzine DMHIDUE Depression 6A70-6A7Z Approved [3]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [4]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [5]
Safinamide mesylate DM0J2ZT Parkinson disease 8A00.0 Approved [6]
Rasagiline DM3WKQ4 Parkinson disease 8A00.0 Approved [7]
Sulphadoxine DMZI2UF Malaria 1F40-1F45 Approved [8]
Pargyline DMM0HR1 Hypertension BA00-BA04 Approved [9]
Indeloxazine DMWO3N6 Dementia 6D80-6D86 Approved [10]
Budipine DMODHQI Migraine 8A80 Approved [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Inhibitor [1]

References

1 Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42.
2 Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
3 Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
4 Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
6 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
7 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
8 Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
9 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
11 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.